Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
It promises fewer injections for vision loss patients
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Subscribe To Our Newsletter & Stay Updated
